Concepedia

Author

Dolores Caballero

Complejo Hospitalario de Salamanca

Also Known As

Ana Sureda, Caballero, D., Carlos Grande, D Caballero, D. Caballero, D.M. Caballero, Diego Duran Caballero, Dolores Caballero, Dolores M. Caballero, Edgar Faber

270

Publications

10.7K

Citations

51

H-Index

63

Concepts

All Affiliations

Complejo Hospitalario de SalamancaHospital de Sant PauInstituto de Investigación Biomédica de SalamancaUniversidad de SalamancaHospital Clínic de Barcelona
DC

About

Dolores Caballero is an author at Complejo Hospitalario de Salamanca specializing in medicine, hematology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

26

39

3.9K

2

Health Sciences

11

11

659

3

Blood Transplantation

11

11

596

4

Cellular Therapies

11

11

573

5

Cell Biology

1

1

68

Dolores Caballero

×

108

Publications

9.7K

Citations

47

H-Index

YearCitations

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John F. Seymour, Fritz Offner,

The Lancet

2010

1.1K

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro,

The Lancet

2018

707

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

Bertrand Coiffier, Barbara Pro, H. Miles Prince,

Journal of Clinical Oncology

2012

664

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown,

The Lancet Oncology

2018

621

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Martin Dreyling, Wojciech Jurczak, Mats Jerkeman,

The Lancet

2015

456

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Anna Sureda, Stephen Robinson, Carmen Canals,

Journal of Clinical Oncology

2007

318

Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients

Jesús F. San Miguel, Antônio Vaz de Macedo, María‐Belén Vídriales,

Blood

1997

273

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

Josè Antonio Pérez-Simón, Panagiotis Kottaridis, Rodrigo Martino,

Blood

2002

243

Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival

David Valcárcel, Rodrigo Martino, Dolores Caballero,

Journal of Clinical Oncology

2007

231

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

Bertrand Coiffier, Barbara Pro, H. Miles Prince,

Journal of Hematology & Oncology

2014

204

Page 1